SOUTH SAN FRANCISCO, Calif., June 13, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it received a letter on June 11, 2008, from the Nasdaq Stock Market, Inc., notifying the company that for the last 30 consecutive business days prior to the letter, the bid price of the Company’s common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 4310(c)(4) (the “Rule”). The letter stated that, in accordance with Marketplace Rule 4310(c)(8)(D), the Company will be provided 180 calendar days, or until December 8, 2008, to regain compliance with the Rule provided the Company is also in compliance with all other listing requirements. For the time being, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “HNAB.”
